These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 35164813)

  • 1. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.
    Archilla-Ortega A; Domuro C; Martin-Liberal J; Muñoz P
    J Exp Clin Cancer Res; 2022 Feb; 41(1):62. PubMed ID: 35164813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.
    Li Y; Zhang Y; Cao G; Zheng X; Sun C; Wei H; Tian Z; Xiao W; Sun R; Sun H
    J Hematol Oncol; 2021 Jun; 14(1):100. PubMed ID: 34174928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selenium-Containing Nanocomplexes Achieve Dual Immune Checkpoint Blockade for NK Cell Reinvigoration.
    Xianyu B; Pan S; Gao S; Xu H; Li T
    Small; 2024 May; 20(19):e2306225. PubMed ID: 38072799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?
    Lanuza PM; Pesini C; Arias MA; Calvo C; Ramirez-Labrada A; Pardo J
    Front Immunol; 2019; 10():3010. PubMed ID: 31998304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
    De Silva P; Aiello M; Gu-Trantien C; Migliori E; Willard-Gallo K; Solinas C
    Int J Cancer; 2021 Jul; 149(1):31-41. PubMed ID: 33252786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoints in the tumor microenvironment.
    Toor SM; Sasidharan Nair V; Decock J; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():1-12. PubMed ID: 31265893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy.
    Zhou X; Chen X; Han L; Liu H
    Clin Sci (Lond); 2022 May; 136(10):771-785. PubMed ID: 35621125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rethinking immune checkpoint blockade: 'Beyond the T cell'.
    Liu X; Hogg GD; DeNardo DG
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
    Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
    Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
    Yan Y; Zhang L; Zuo Y; Qian H; Liu C
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.